1 Global Reusable Insulin Pens Market Insight Analysis
The global reusable insulin pens market is valued at USD 747.86 million in 2024, with a CAGR of 5.72% from 2024 to 2033.
Insulin pens are devices used for diabetes patients to inject insulin into the patient’s body in the desired quantity. The insulin pen is slightly larger than the writing pen in size and it contains the insulin in the refill. Insulin pens have made it convenient and less painful for diabetic patients to take insulin. Not only insulin pen injects a precise amount of insulin into the body but also it may be done in fewer steps than a syringe. Reusable pens work with insulin cartridges that can be loaded into the pen and then tossed away once the insulin is used, leaving the pen ready for the next cartridge. Each pen only works with certain types of insulin.
Figure Global Reusable Insulin Pens Market Size (M USD) and CAGR (2024-2033)
2 Reusable Insulin Pens Market Growth Drivers and Restraints
Rising incidence of diabetes: As a chronic disease, the number of people suffering from diabetes continues to increase worldwide. According to the International Diabetes Federation (IDF), about 425 million people suffered from diabetes in 2017, and it is expected to reach 629 million by 2045. Among them, 5-10% of patients have type 1 diabetes and need to inject insulin regularly. The increase in the number of patients with diabetes has directly driven the market demand for insulin pens, becoming a key driver of market growth.
Combination of technological progress and artificial intelligence: With the development of science and technology, reusable insulin pens are becoming more intelligent. For example, the “InPen™” smart insulin pen launched by Medtronic can connect to smartphones, analyze data in real time, and provide patients with personalized insulin dosage recommendations. The application of artificial intelligence technology makes the functions of insulin pens more diversified and humanized, meets patients’ needs for precision medicine, and stimulates the growth of market demand for smart insulin pens.
Increased investment and awareness in healthcare: Countries have continuously increased their investment in the healthcare field, improving the diagnosis and treatment of diabetes. At the same time, people’s awareness of diabetes and increased attention to the risk of needlestick injuries have led more patients to choose to use insulin pens for insulin injections, which has promoted the development of the market.
The Asia-Pacific region has great market potential: The Asia-Pacific region has a large group of diabetic patients, with a large number of patients in China and India. Insulin, as the core drug for diabetes treatment, makes the region an important market for reusable insulin pens. Global manufacturers have deployed in the Asia-Pacific region, further promoting the growth of the market.
Price factors affect demand: Insulin pens, especially smart insulin pens, have increased costs and prices as their functions increase. About half of the patients who need insulin in the world cannot afford it, which limits the market demand for insulin pens. While pursuing profits, companies find it difficult to balance the relationship between product prices and market demand, which has become a major challenge for market development.
Limitations of product use: Different types of insulin cannot be mixed in insulin pens. When patients need mixed injections, they need to use two pens for injection separately, which brings inconvenience to patients and affects the product experience.
3 Technological Innovations in the Reusable Insulin Pens Market
Significant trend of intelligent development: Insulin pens on the market are moving towards intelligence. Bluetooth-connected and USB-connected smart insulin pens are emerging, such as Novo Nordisk’s related products, which can record and store the latest 800 dose information, including injection units and time. Medtronic’s “InPen™” smart insulin pen can not only track the user’s insulin usage, but also calculate the dose, remind medication, etc., and can be connected to smartphone applications to achieve data visualization, which is convenient for patients to manage their conditions and for medical staff to monitor.
Technological progress improves product performance: Some insulin pens have been improved in technology, such as the ServoPen with a spring-driven mechanism, which makes injection easier and reduces the injection burden on patients. Some insulin pens are also equipped with functions such as automatic image recognition to improve the accuracy and safety of injections.
Integration with other medical technologies: There is a clear trend of integration between insulin pens and other medical technologies. Novo Nordisk has cooperated with Abbott to integrate insulin dose data into digital health tools, connect key technologies such as continuous blood glucose monitoring and insulin pens, and simplify the diabetes management process. Eli Lilly has reached a strategic cooperation with a number of diabetes technology companies to integrate data and technology to improve the efficiency of diabetes management.
Improve corporate competitiveness: Companies integrate resources through mergers and acquisitions to improve their competitiveness in the market. Medtronic acquired Companion Medical and obtained the InPen smart insulin pen system, further enriching its diabetes management product line and strengthening its market position in the field of diabetes treatment. This acquisition enables Medtronic to combine InPen with its own intelligent algorithms to provide more personalized and accurate treatment plans for diabetic patients.
4 Global Reusable Insulin Pens Market Size by Type
Refillable insulin pens have long been a staple in the market. In 2024, they are projected to generate a revenue of 486.71 million USD. This significant revenue is a testament to their wide acceptance and usage among patients, especially those who prefer a more straightforward and cost-effective option. Their market shares in 2024 is approximately 65.08% of the total market revenue.
These pens are favored by patients with low flexibility, poor eyesight, or those who require portability for timely administration. Their simplicity in design and operation makes them easy to use, which is a crucial factor for many patients. For example, in regions with a large elderly diabetic population, such as parts of Europe and North America, refillable insulin pens continue to be popular due to their user – friendly nature. Although they are generally less intelligent compared to smart insulin pens, meeting only the basic functions of insulin pens, their reliability and affordability contribute to their substantial market share.
Bluetooth – connected smart insulin pens have witnessed remarkable growth in the market. In 2024, they are expected to earn a revenue of 201.10 million USD, accounting for about 26.89% of the market share. These pens, combined with intuitive mobile applications, offer a revolutionary way for diabetic patients to manage their insulin intake.
They can help patients take the right amount of insulin at the right time by providing real – time reminders and tracking dose history. This technology is particularly beneficial for patients who need to closely monitor their insulin usage and share data with healthcare professionals. In more tech – savvy regions like North America and parts of Asia – Pacific, such as South Korea and Japan, the adoption of Bluetooth – connected smart insulin pens has been on the rise. The convenience of seamless data transfer between the pen and a mobile device, along with features like missed dose reminders, makes these pens an attractive option for patients who are comfortable with using digital technologies in their healthcare management.
USB – connected smart insulin pens are another important segment in the market. In 2024, they are estimated to generate a revenue of 60.05 million USD, with a market share of around 8.03%. These pens can transfer data to a computer and charge the pen battery, and some are equipped with a motor – drive device for more accurate measurement in 0.1 unit increments.
This level of precision is highly valued by patients who require strict control over their insulin doses. Although their market share is relatively smaller compared to refillable and Bluetooth – connected smart insulin pens, they still play a crucial role in the market. In regions where advanced medical technology is readily accessible and patients have a high demand for accurate dosing, such as in some European countries and the United States, USB – connected smart insulin pens have found their niche. Their ability to interface with computers also allows for more in – depth data analysis, which can be useful for healthcare providers in developing personalized treatment plans for patients.
Table Global Reusable Insulin Pens Market Size and Share by Type in 2024
|
Type |
Market Size (M USD) 2024 |
Market Share 2024 |
|---|---|---|
|
Refillable Insulin Pens |
486.71 |
65.08% |
|
Bluetooth Connected Smart Insulin Pens |
201.10 |
26.89% |
|
USB Connected Smart Insulin Pens |
60.05 |
8.03% |
5 Global Reusable Insulin Pens Market Size by Application
In 2024, the hospital pharmacy segment is expected to generate a significant revenue of 317.76 million USD. It holds a substantial market share, accounting for approximately 42.49% of the total market revenue. Hospital pharmacies are crucial distribution channels for reusable insulin pens. They stock a wide range of medications, including specialized and investigational drugs, and play a vital role in providing patients with access to insulin pens.
The high revenue in this segment can be attributed to the large number of patients who obtain insulin pens directly from hospitals, especially those with complex medical conditions or in need of immediate access to the devices. For example, in North America, many patients rely on hospital pharmacies for their insulin pen needs, contributing to the segment’s strong revenue performance.
The retail pharmacy segment is also an important part of the market. In 2024, it is projected to earn 145.68 million USD in revenue, with a market share of around 19.48%. Retail pharmacies offer convenience to patients, allowing them to purchase insulin pens over – the – counter or with a prescription. They serve as a primary source for patients who prefer to pick up their medications at local stores.
In regions like Europe, retail pharmacies have a well – developed network, and the demand for insulin pens in these locations is consistent, contributing to the segment’s revenue. The growth in this segment is also influenced by the increasing availability of insulin pens in retail chains and the convenience of one – stop shopping for patients.
Diabetes clinics are another significant application area. In 2024, they are expected to have a revenue of 234.07 million USD, with a market share of about 31.30%. These clinics are dedicated to the diagnosis and treatment of diabetes, and they often recommend and sell insulin pens to patients. The revenue in this segment is driven by the personalized care and professional advice that diabetes clinics provide. Patients trust the recommendations of medical experts in these clinics, which leads to a higher likelihood of purchasing insulin pens. For instance, in Asia – Pacific, the growing number of diabetes clinics and the increasing awareness of proper diabetes management are fueling the demand for insulin pens in this segment.
The online sales segment has been growing steadily. In 2024, it is estimated to generate 50.35 million USD in revenue, with a market share of around 6.73%. The rise of e – commerce has made it easier for patients to purchase insulin pens online. Online sales offer several advantages, such as a wider product selection, competitive pricing, and the convenience of home delivery.
In regions where online shopping is popular, like North America and parts of Asia – Pacific, the online sales segment has seen significant growth. However, it still has a relatively smaller market share compared to traditional distribution channels like hospital pharmacies and retail pharmacies, mainly due to concerns about product authenticity and the need for some patients to obtain medical advice before purchasing.
Table Global Reusable Insulin Pens Market Size and Share by Application in 2024
|
Application |
Market Size (M USD) 2024 |
Market Share 2024 |
|---|---|---|
|
Hospital Pharmacy |
317.76 |
42.49% |
|
Retail Pharmacy |
145.68 |
19.48% |
|
Diabetes Clinics |
234.07 |
31.30% |
|
Online Sales |
50.35 |
6.73% |
6 Global Reusable Insulin Pens Market Size by Region
In 2024, North America is expected to have a market revenue of 151.36 million USD. The region has a well – developed healthcare system and a high prevalence of diabetes, which drives the demand for reusable insulin pens. The United States, in particular, is a major market within North America. The growth in North America is also supported by the presence of leading pharmaceutical companies and a high level of healthcare spending.
For example, the increasing adoption of smart insulin pens in North America is a notable trend. Companies like Novo Nordisk, Sanofi Diabetes, and Eli Lilly and Company have a strong market presence here, and their continuous innovation in insulin pen technology, such as the development of Bluetooth – connected and USB – connected smart insulin pens, is fueling market growth. The region’s consumers are also more likely to embrace new technologies, which further promotes the sales of advanced insulin pens.
Europe is another major market for reusable insulin pens, with an expected revenue of 278.80 million USD in 2024. It has a long – standing history in the pharmaceutical and medical device industries. Countries like Germany, France, the UK, and Italy have a large patient population with diabetes, and the healthcare systems in these countries provide significant support for diabetes treatment.
Europe also has a high level of acceptance for reusable medical devices, and the market here is characterized by strong competition among manufacturers. For instance, companies based in Europe, such as Ypsomed, have been actively involved in the development of innovative insulin pen technologies. The region’s strict regulatory environment also ensures the quality and safety of insulin pens, which builds consumer trust and drives market growth.
The Asia – Pacific region is emerging as a crucial market for reusable insulin pens, with an estimated revenue of 260.48 million USD in 2024. The region has a large and growing diabetic population, especially in countries like China and India. In China, the increasing awareness of diabetes management and the expansion of the healthcare system are driving the demand for insulin pens.
The growth in Asia – Pacific is also supported by the improving economic conditions in many countries, which enable more patients to afford insulin pens. Additionally, the region is seeing a growing trend of adopting advanced medical technologies, although the pace of adoption may vary from country to country. For example, in more developed economies like Japan and South Korea, the adoption of smart insulin pens is relatively faster compared to some other countries in the region.
Latin America is a developing market for reusable insulin pens, with an expected revenue of 32.44 million USD in 2024. The region has a significant number of diabetes patients, but the market is still in the process of development. The growth in Latin America is influenced by factors such as the increasing investment in healthcare infrastructure and the growing awareness of diabetes treatment. Brazil, Argentina, and Mexico are the major markets in the region. However, the market here also faces challenges such as lower purchasing power in some areas, which may limit the adoption of high – end insulin pens. Despite these challenges, the market shows potential for growth as more affordable and innovative products are introduced.
The Middle East & Africa region has an expected revenue of 24.78 million USD in 2024. The prevalence of diabetes in some countries in this region, such as Saudi Arabia and Turkey, is relatively high. The market in this region is growing, but it also faces challenges like limited healthcare resources in some areas and differences in the affordability of insulin pens. However, with the increasing investment in healthcare and the growing awareness of diabetes management, the market for reusable insulin pens is expected to expand in the future. For example, the government initiatives in some countries to improve diabetes care are likely to drive the demand for insulin pens in the region.
Figure Global Reusable Insulin Pens Market Size (M USD) by Region in 2024
7 Global Reusable Insulin Pens Market Analysis by Major Players
Novo Nordisk
Company Introduction and Business Overview:
Novo Nordisk is a leading global healthcare company headquartered in Denmark. Founded in 1923, the company has a long history of innovation and excellence in the field of diabetes care. Novo Nordisk is renowned for its commitment to improving the lives of people with diabetes through the development of advanced insulin delivery systems and pharmaceuticals. The company operates in over 80 countries and employs more than 40,000 people worldwide.
Novo Nordisk’s business is centered around the research, development, manufacturing, and marketing of pharmaceutical products and medical devices for diabetes management. The company’s core focus areas include insulin therapies, diabetes care devices, and related technologies. Novo Nordisk is particularly known for its innovative approach to diabetes treatment, combining advanced pharmaceuticals with user-friendly delivery systems. The company’s strong R&D capabilities and strategic partnerships have enabled it to maintain a leading position in the global diabetes market.
Products:
Novo Nordisk offers a comprehensive range of reusable insulin pens, including both traditional refillable pens and advanced smart insulin pens. Their flagship product, the NovoPen Echo, is a refillable insulin pen designed for ease of use and convenience. It features a simple dosing mechanism and a compact design, making it suitable for both adults and children with diabetes.
Additionally, Novo Nordisk has introduced the NovoPen 6 and NovoPen 5, which are Bluetooth-enabled smart insulin pens. These pens integrate with mobile applications to provide users with real-time dose tracking, insulin usage analytics, and personalized reminders. This combination of traditional and smart insulin pens allows Novo Nordisk to cater to a wide range of user needs and preferences.
Sanofi Diabetes
Company Introduction and Business Overview:
Sanofi is a multinational pharmaceutical company headquartered in France. Established in 2004 through the merger of Aventis and Hoechst Marion Roussel, Sanofi has grown to become a global leader in the healthcare industry. The company is dedicated to discovering and developing innovative treatments for a variety of medical conditions, with a strong focus on diabetes, immunology, and rare diseases. Sanofi operates in over 100 countries and employs more than 100,000 people worldwide.
Sanofi’s business spans across multiple therapeutic areas, including diabetes, cardiovascular diseases, and oncology. The company’s diabetes division is particularly notable for its comprehensive approach to diabetes management, encompassing both pharmaceuticals and medical devices. Sanofi’s commitment to innovation and patient care has led to the development of advanced insulin delivery systems that improve the quality of life for people with diabetes. The company’s strong R&D pipeline and strategic collaborations with academic institutions and biotech companies further enhance its market position.
Products:
Sanofi offers a diverse range of reusable insulin pens designed to meet the needs of different patient populations. Their flagship product, the SoloStar pen, is a widely used refillable insulin pen known for its user-friendly design and reliability. The SoloStar pen features a simple dosing mechanism and a clear display, making it easy for patients to administer their insulin doses accurately.
In addition to the SoloStar pen, Sanofi has also introduced the Lantus SoloStar, a prefilled insulin pen designed for ease of use and convenience. This pen is particularly popular among patients who require long-acting insulin therapy. Sanofi’s product portfolio also includes smart insulin pens that integrate with digital health platforms, providing users with enhanced features such as dose tracking and insulin usage analytics.
Eli Lilly and Company
Company Introduction and Business Overview:
Eli Lilly and Company is a global pharmaceutical corporation headquartered in Indianapolis, USA. Founded in 1876, Eli Lilly has a long history of innovation and excellence in the field of healthcare. The company is dedicated to improving the lives of patients through the discovery and development of high-quality pharmaceuticals and medical devices. Eli Lilly operates in over 120 countries and employs more than 40,000 people worldwide. The company’s strong commitment to R&D and patient care has enabled it to maintain a leading position in the global healthcare market.
Eli Lilly’s business focuses on the development and marketing of pharmaceutical products across multiple therapeutic areas, including diabetes, oncology, and immunology. The company’s diabetes division is particularly notable for its innovative approach to insulin therapy and delivery systems. Eli Lilly’s commitment to improving diabetes management has led to the development of advanced insulin products and user-friendly delivery devices. The company’s strong R&D capabilities and strategic partnerships with other industry leaders further enhance its market position and ability to deliver innovative solutions to patients.
Products:
Eli Lilly offers a comprehensive range of reusable insulin pens designed to meet the diverse needs of patients with diabetes. Their flagship product, the Humalog KwikPen, is a widely used refillable insulin pen known for its reliability and ease of use. The KwikPen features a simple dosing mechanism and a compact design, making it suitable for both adults and children with diabetes.
In addition to the KwikPen, Eli Lilly has also introduced the Humalog Mix KwikPen, a prefilled insulin pen designed for patients who require a combination of rapid-acting and long-acting insulin. Eli Lilly’s product portfolio also includes smart insulin pens that integrate with digital health platforms, providing users with enhanced features such as real-time dose tracking and insulin usage analytics. These advanced pens are particularly attractive to tech-savvy patients and healthcare providers seeking innovative diabetes management solutions.